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ABSTRACT: Malaria caused by the protozoan parasite Plasmodium falciparum (Pf) remains a
major public health problem throughout the developing world. One molecular target that
should receive more attention is the molecular chaperone Hsp90. It is essential and highly
conserved in all eukaryotes, including in protozoan parasites. We have identiﬁed an amino-
alcohol carbazole (N-CBZ) as a PfHsp90-selective inhibitor by virtually docking a large set of
antimalarial compounds, previously found in a phenotypic screen, into a PfHsp90-speciﬁc
pocket. By correlating the ability of 30 additional N-CBZ derivatives to bind directly to
PfHsp90 with their Pf-inhibitory activity, we found that these types of compounds are more
likely to inhibit Pf growth if they bind PfHsp90. For plausible targets such as PfHsp90, our
workﬂow may help identifying the molecular target for compounds found by screening large
chemical libraries for a desired biological eﬀect and, conversely, ensuring biological eﬀectiveness
for compounds aﬀecting a particular target.
■ INTRODUCTION
Malaria is caused by infection with protozoan parasites such as
Plasmodium falciparum (Pf). It remains a deadly disease that
aﬀects 104 countries, causing a global death toll of more than
600000 and putting 3.4 billion people in danger. Eﬀective
antimalarials are therefore indispensable tools for public health
in many countries. Unfortunately, current antimalarial drugs are
rapidly losing their eﬀectiveness because of arising parasite
resistance. This calls for the discovery and development of
novel agents with high eﬀectiveness and selectivity.1,2 More and
more of these recent eﬀorts have used combinations of
computational and experimental strategies to target a variety of
cellular processes of Pf.3,4
Hsp90 is a highly abundant and conserved cytosolic
molecular chaperone, which is essential to maintain protein
homeostasis in eukaryotes.5,6 This also applies to protozoan
parasites: Numerous pharmacological studies with generic
Hsp90 inhibitors have established the parasite Hsp90 as a
molecular target against malaria; inhibition of Hsp90 of Pf
(PfHsp90) not only blocks the lifecycle of the parasite at the
red blood cell stage but also leads to parasitemia clearing in a
mouse model.7−15 Another relevant aspect of Hsp90 biology is
that Hsp90 supports the development of drug resistance both
in Pf and pathogenic fungi, and Hsp90 inhibitors therefore not
only interfere with a multitude of essential cellular functions but
also many resistance mechanisms.15−18 Hence, inhibitors
targeting Hsp90 hold great promise as next-generation
antimalarial drugs, notably if they can be developed to be
selective for Hsp90 of the parasite over that of the human
host.19,20 The problem is that PfHsp90 has a very high
sequence homology with its human orthologues, which has
impeded the development of the known Hsp90 inhibitors into
realistic treatment options for malaria. To overcome this issue,
we recently reported a novel drug design strategy which takes
advantage of a Pf-speciﬁc drug binding pocket in PfHsp90. This
allowed us to discover a 7-azaindole as a species-selective
PfHsp90 inhibitor.20 Despite binding PfHsp90 in a species-
selective fashion and inhibiting Pf proliferation in culture, this
7-azaindole still requires substantial optimization of binding
aﬃnity, antimalarial potency, and presumably its pharmaco-
logical proﬁle.
High-throughput phenotypic screens of large compound
libraries have yielded many new antimalarial candidates in the
past few years.21−26 These compounds have high potency and
selectivity against Pf and excellent pharmacological proﬁles.
Phenotypic screens are undoubtedly a powerful approach to
discover novel lead compounds. Their big advantage is that
from the outset it is clear that hits have the desired eﬀect in a
given biological assay system. One of the main disadvantages,
however, is that they do not automatically reveal the molecular
target(s) whose inhibition or activation underlie the biological
eﬀects. Without knowing the molecular target and mechanism
of action, any further rational drug development is severely
compromised. This dilemma prompted us to consider
combining opposite drug discovery strategies. Here, we
propose a reversed drug discovery approach that aims at
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discovering PfHsp90 inhibitors among libraries of potent but
poorly characterized antimalarial compounds.
■ RESULTS
We hypothesized that Hsp90-targeting compounds may be
represented in a library of antimalarial compounds of suﬃcient
chemical diversity and designed a strategy to identify and to
characterize them (Figure 1). We took all 172 validated
antimalarial compounds from a previously published large
phenotypic screen21 and docked them in silico within the Pf-
speciﬁc drug binding pocket of PfHsp90. To validate and reﬁne
the in silico docking results, we performed molecular dynamics
(MD) simulations using the original docking pose of the 10
top-ranked hits (Supporting Information, Table S1) in the Pf-
speciﬁc drug binding pocket of PfHsp90 and examined their
interaction and stability along the simulation (Figure 2). While
most of the compounds became unstable and eventually
dissociated, we noticed that compound SJ000111021 (hereafter
referred to as compound 5E) retained its original pose and
demonstrated a high stability inside the Pf-speciﬁc pocket. 5E is
a compound based on aminoalcohol-carbazole (N-CBZ). We
cross-validated this result with Glide, another docking software,
Figure 1. Workﬂow for identifying and characterizing antimalarial compounds that target PfHsp90.
Figure 2. MD simulation of 10 hits preselected by docking to PfHsp90 from 172 antimalarial compounds. The nomenclature of the compounds is
the original one from the publication by Guy and colleagues.21 The structure of compound SJ000111021 (referred to here as 5E), which displays a
prominent interaction stability in the Pf-speciﬁc drug binding pocket of PfHsp90, is shown on the right.
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and found a predicted top pose which was very similar to that
obtained with the original docking and MD simulations
(Supporting Information, Table S2). The predicted pose has
the tricyclic CBZ ring, together with a chloride at its 3-position,
anchored in the Pf-speciﬁc pocket delimited by THR101,
PHE104, and the glycine-rich hinge loop between GLY118 and
GLY123 (Figure 3). Both the hydroxyl group and the
secondary amine on the N-alkyl branch of 5E are predicted
to form H-bonds with the deprotonated carboxyl group on the
side chain of GLU33 of PfHsp90. This model suggests that the
chloro-CBZ core of 5E provides the main van der Waals
interaction with the surrounding residues of the Pf-speciﬁc
pocket of PfHsp90 while the N-alkyl chain essentially
contributes an electrostatic interaction. These in silico studies
indicated that N-CBZ derivatives such as compound 5E may
target PfHsp90.
For our next experimental steps, we acquired 30 N-CBZ
derivatives and subjected them to a structure−activity relation-
ship (SAR) analysis. To determine whether these compounds
indeed bind PfHsp90, we performed microscale thermopho-
resis experiments with recombinant PfHsp90. This technology
exploits the ligand-induced changes in the molecular move-
ments of the ﬂuorescently labeled protein in a temperature
gradient, which are a measure of its binding aﬃnity. We
determined the thermophoresis shifts of all compounds at a
ﬁxed concentration of 50 μM (Table 1 and Supporting
Information, Tables S2 and S3). These analyses revealed that
many N-CBZ derivatives directly bind to PfHsp90 and
conﬁrmed the in silico prediction with compound 5E. Because
this SAR analysis indicated marked diﬀerences between
compounds, we sought to identify the molecular determinants
of binding. This analysis was performed with ChemmineR,27 a
basic tool for quantitative SAR (QSAR). We clustered the
compounds by chemical similarity and displayed the
hierarchical tree along with the binding results represented as
a heatmap (Figure 4, Table 1, and Supporting Information,
Table S3). This clearly segregates the compounds into two
groups where those of group 1, which are characterized by a
piperazine group at the end of the N-alkyl group, appear more
likely to bind PfHsp90. We selected compound 5B as a
representative of group 1 and determined its binding aﬃnity for
PfHsp90 and human Hsp90β by microscale thermophoresis
(Figure 5 and Table 1). We found that 5B binds PfHsp90 with
a Kd of 28.1 μM but does not bind human Hsp90β at all. The
closely related chemical 3B binds PfHsp90 with a Kd of 25.6
μM (Supporting Information, Figure S1). The pan-Hsp90
inhibitor geldanamycin binds Hsp90 from both species with
similarly high aﬃnities.
Considering our modeling and in vitro binding experiments,
it seemed likely that 5B binds in the Pf-speciﬁc pocket of
PfHsp90. To provide experimental evidence for this hypothesis,
we proceeded with binding studies using the PfHsp90 triple
mutant ISG-LGA (I108L, S111G, G112A), in which the Pf-
speciﬁc pocket is closed and resembles the conﬁguration of
human Hsp90α. As expected, the PfHsp90 ISG-LGA changes
prevent the binding of 5B (Figure 5). In contrast,
Figure 3. Proposed docking pose of compound 5E in the Pf-speciﬁc
drug binding pocket of PfHsp90 (labeled in red).
Table 1. Structures, Biochemical, and Biological Activities of
Tested Compoundsa
a*This compound is identical to compound 14a in ref 28.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.6b00591
J. Med. Chem. 2016, 59, 6344−6352
6346
geldanamycin, which does not use the Pf-speciﬁc pocket for
binding, binds the triple mutant with similar aﬃnity. These
ﬁndings strongly support the conclusion that compound 5B
binds PfHsp90 in a species-selective fashion because of its
engagement of the Pf-speciﬁc pocket.
To provide further computational support for the direct
binding of 5B in the Pf-speciﬁc drug binding pocket of
PfHsp90, we performed docking studies using Glide (Support-
ing Information, Table S2 ). We found that two prominent
poses can be predicted and that in both cases the chloro-CBZ
core occupies the Pf-speciﬁc pocket (Figure 6). In predicted
pose 1, the CBZ core adopts a “ﬂipped-in” conformation with
its N-alkyl branch reaching into the Hsp90 ATP binding pocket
surrounded by ASN37, ASP79, VAL122, GLY123, THR171,
and ILE173. In contrast, predicted pose 2 consists of a “ﬂipped-
out” CBZ conformation, leaving the Hsp90 ATP and standard
drug binding pocket vacant. In this case, the N-alkyl branch
protrudes over the glycine-riched loop (GLY118 to GLY123) at
the entrance of the Hsp90 ATP binding pocket. The predicted
pose 2 for 5B is very similar to the favored docking pose of 5E
(compare Figures 3 and 6), and for both compounds, there are
H-bonds between the carboxyl group of GLU33 and the N-
alkyl group.
At this point, we had established that some N-CBZ
compounds bind PfHsp90 directly, albeit with modest aﬃnity,
and can be modeled into the Pf-speciﬁc pocket. We selected a
representative set of N-CBZ derivatives from groups 1 and 2
and tested their ability to inhibit the proliferation of Pf in
culture (Table 1). We found remarkably potent candidates with
IC50s of less than 200 nM in both groups, including the two
molecules (5E and 5B) that we had investigated in more detail.
These also displayed only moderate cytotoxicity in rat L6 cells,
which are a valid in vivo model for human Hsp90 considering
that human and rodent Hsp90s are 99% identical. In L6 cells,
the whole panel of compounds gave a wide range of toxic
concentrations (Table 1); this is consistent with the notions
that some PfHsp90-selective inhibitors may still bind
mammalian Hsp90 to some extent, albeit with poor aﬃnity
and thus low occupancy20 and/or target a variety of other
molecules. Interestingly, Guy and colleagues had reported
considerably higher IC50 values against Pf for compound 5E,
ranging from 0.48 to 1.8 μM in Pf strains K1 and 3D7,
respectively,21 compared to 82 nM in our own tests with the Pf
strain NF54. The IC50s reported by Routier and colleagues in
their characterization of N-CBZ antimalarial activities with Pf
strain K128 are far more consistent with those that we have
determined. Apart from strain diﬀerences, additional exper-
imental diﬀerences must explain these apparent numerical
discrepancies. In any case, all of these data then allowed us to
explore whether there is a correlation between PfHsp90
binding and inhibition of Pf in culture. As can be seen in
Figure 7, compounds with weak PfHsp90 binding (with a
thermophoresis shift <5) are much less likely to have an IC50
lower than 1 μM, with the exception of compound 2E. In
contrast, compounds with stronger binding to PfHsp90 (with a
thermophoresis shift >5) tend to have an IC50 lower than 100
μM, as exempliﬁed most prominently by compounds 5B, 2D,
5E, and 5A.
■ DISCUSSION AND CONCLUSIONS
Phenotypic screens for active compounds can yield interesting
candidates but may not provide any insights into their
molecular targets. We developed a workﬂow (Figure 1) to
deorphanize active compounds in a context where the
molecular chaperone Hsp90 was a plausible target. We
discovered that a library of previously identiﬁed antimalarial
compounds21 contained an N-CBZ whose molecular target is,
or at least includes, PfHsp90.
CBZ derivatives have been known for their antimalarial
potency for some time.29,30 N-Substituted CBZ derivatives
were ﬁrst identiﬁed as potent antimalarials with a phenotypic
screen against the chloroquine-resistant Pf strain K1.26 More
recently, an extensive SAR analysis of the derivatives bearing
modiﬁcations at the 3- and/or 6-positions and the N-alkyl of
the CBZ core led to the identiﬁcation of several N-CBZ
derivatives with promising antimalarial and pharmacokinetic
characteristics.28 The N-CBZ pharmacophore came up in our
own pipeline through an entirely diﬀerent and unbiased
approach when we discovered compound 5E, one of 172, in
the antimalarial library of compounds found in a phenotypic
screen with almost 400000 compounds.21 However, neither the
N-CBZ-targeted28 nor the high-throughput screen21 provided
any clues as to the potential drug targets and mechanisms of
Figure 4. Scheme juxtaposing ligand binding data and clustering by
chemical similarity. Binding of N-CBZ derivatives to PfHsp90 at 50
μM was determined by microscale thermophoresis, and the results are
represented as a heat map where red corresponds to a large shift and
thus stronger binding (higher aﬃnity). The chemicals are clustered
based on chemical similarity. The PfHsp90-selective 7-azaindole
compound IND3111920 is included as an outgroup and for
comparison.
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Figure 5. Microscale thermophoresis measurements of the binding aﬃnities of compound 5B and geldanamycin for PfHsp90, human Hsp90β, and
the PfHsp90 triple mutant ISG-LGA.
Figure 6. Proposed docking poses of compound 5B in the Pf-speciﬁc drug binding pocket of PfHsp90 (labeled in red). See text for more details.
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action. Here, we have ﬁlled this gap by demonstrating that
PfHsp90 is at least one target for some N-CBZ derivatives and
that promising compounds may not target Hsp90s of the
human host because those lack the binding pocket that they
engage in PfHsp90.20 In fact, this may also explain why CBZ-
based compounds had not been encountered before as Hsp90
inhibitors.31 With the exception of the chemically slightly
diﬀerent carbazol-4-one molecules,32 CBZ may not bind the
canonical ATP-binding pocket of human Hsp90 (see also
below).
The speciﬁcity of our workﬂow consisted of starting from the
bold assumption that there could be Hsp90 inhibitors in a large
set of antimalarial compounds and in screening them in silico
and subsequently experimentally. It is this combination that
allowed us to circumvent the high false-positive rates typically
associated with docking results.33 First, we performed MD
simulations of candidates that were top ranked in the primary
docking analysis. This step was helpful to ﬁlter out the false
positive candidates, which can be expected to dissociate rapidly
along the MD simulation. MD simulations provided a relatively
fast method with suﬃcient granularity for ﬁltering compounds
further before subsequent more in-depth modeling. Compound
5E was the sole candidate that stably interacted with the Pf-
speciﬁc pocket of PfHsp90 through both van der Waals and
electrostatic interactions (Figures 2 and 3). Second, because the
SAR analyses of a large set of compounds can be time-
consuming and complicated, we applied a chemoinformatic
analysis by which the degree of similarity of compounds can be
quantitatively represented by algorithmic distances and
eventually displayed by hierarchical clustering (Figure 4).
Third, we directly tested PfHsp90 binding of a panel of N-CBZ
derivatives based on the structure of 5E and found that many,
although not all, of the derivatives do indeed bind PfHsp90.
The hierarchical clustering based on chemical similarity
revealed as a clear trend that compounds with a piperazine
group at the end of the N-alkyl (compounds in group 1, Figure
4) are more likely to bind to PfHsp90. This preferential binding
suggests of a route for further optimization. It should be
mentioned that interesting hits such as 5E could also be found
within group 2 compounds, but elongated decorations at the N-
alkyl seem to contribute to a better binding aﬃnity (Table 1).
Most well-characterized Hsp90 inhibitors bind to the highly
conserved N-terminal ATPase pocket and, therefore, their
species selectivity is weak.20,31,34−36 PfHsp90 diﬀers from
human Hsp90 by the Pf-speciﬁc pocket, a hydrophobic pocket
which extends from the conserved ATP-binding pocket.20,37
Compounds that rely on binding to the Pf-speciﬁc pocket of
PfHsp90 are excellent candidates for the design of PfHsp90-
selective inhibitors.20 With this in mind, we performed the
docking of all molecules in the Pf-speciﬁc pocket rather than
the common drug-binding pocket of Hsp90. Noticing an
abundance of PfHsp90 binders in group1 compounds, we
selected 5B for further in-depth analysis. We experimentally
determined its binding aﬃnity and conﬁrmed its species
selectivity. This conclusion could be further supported by
showing that the PfHsp90 triple mutant ISG-LGA, which
resembles human Hsp90 around the Pf-speciﬁc pocket, fails to
bind 5B (Figure 5). Thus, it is reasonable to assume that the
predicted contacts of 5B within the Pf-speciﬁc pocket (Figure
6) account for the species selectivity of this compound.
Our SAR analysis revealed that compounds with similar
PfHsp90 binding aﬃnities can exhibit very distinct antimalarial
potency: compound 3B only diﬀers from 5B by an extra
carboxylate within the N-alkyl branch between the piperazine
and the benzene groups, but this addition decreases the
antimalarial activity by more than 1 order of magnitude (Table
1). We also found that the removal of halogens at R2 is
detrimental to the growth inhibitory activity but does not
always reduce binding to PfHsp90 (Table 1, compare 5B/2D
to 2B and 5A to 2E). Previous studies had indicated that strong
inhibition of PfHsp90 alone is suﬃcient for eﬀective
antimalarial activity.7,8,12,14 In the case of compound 5B, a
good representative of our set of active N-CBZ compounds,
there is an obvious gap between its PfHsp90 binding aﬃnity
(Kd = 24 μM) and its potency in inhibiting Pf growth (IC50 =
82 nM) (Table 1). This supports the speculation that N-CBZ
compounds such as 5B are growth inhibitory for Pf by
inhibiting both PfHsp90 and other critical target proteins that
have yet to be identiﬁed. In any case, our studies support the
speculation that high aﬃnity inhibitors of PfHsp90 are more
likely to be eﬀective antimalarials (Figure 7). All of this
evidence suggests that rigorous and comprehensive QSAR38,39
programs through two distinct medicinal chemistry routes
might be required to optimize the PfHsp90 binding aﬃnity
while maintaining or even improving the antimalarial activity
and reducing the cytotoxicity for human cells even further.
■ EXPERIMENTAL SECTION
Reagents. Geldanamycin was purchased from LC Laboratories and
the N-CBZ compounds (as racemic mixtures) from Chembridge (San
Diego, CA). All compounds were ≥95% pure; according to the
manufacturer, the structures and 99% purity of the tested compounds
were conﬁrmed by LC/MS (see Supporting Information). All
chemicals were dissolved in 100% DMSO to 10 mM and stored at
−20 °C.
Compound Library and Docking. The in silico library of the 172
antimalarial compounds was extracted from the publication by Guy
and colleagues21 and prepared with the ZINC database, including all
possible enantiomers (each enantiomer was treated as an individual
compound).40 The protein model of PfHsp90 was obtained from the
Figure 7. Structure-independent correlation between stronger
PfHsp90 binding and more potent antiproliferative potency against
Pf. Shifts larger or smaller than 5 in the microscale thermophoresis
experiment are indicative of a higher or lower aﬃnities, respectively.
All compounds tested for activity against Pf are grouped according to
their apparent binding aﬃnities and placed on the Y axis by IC50 in the
Pf proliferation assays. Student’s t test was performed comparing the
groups with high (n = 9) and low (n = 10) thermophoresis shifts (p
value = 0.0154).
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crystal structure of PfHsp90 (PDB code 3K60, chain A).37 Solvent and
ligand were removed. The model was minimized for 1000 steps
(steepest descent) before generation of the grid and spheres in the
DOCK 6 package (UCSF).41 The screening was performed using
DOCK 6.3 (UCSF). All ranked candidates were rescored with the
DOCK 6 AMBER package.42 The top 10 candidates were selected and
subjected to further MD simulations. For in-depth predictions of
binding poses, compounds 5E and 5B with both R- and S-enantiomers
were docked in the PfHsp90 model using Glide (Schrödinger) in the
XP (extra-precision) mode.43−45 The docking results from DOCK 6
and Glide and explicit descriptions of force ﬁelds used for docking are
found in Supporting Information, Table S1.
Molecular Dynamics. Ligands were removed from the PfHsp90
model (PDB 3K60), and the rest of the structure, including structural
water molecules, was parametrized by FF11 from AMBER11.47. A
solvent box of 8 Å was generated around the protein in the presence of
counterions to equilibrate the charges.46 The models were ﬁrst
minimized in ACEMD for 250 steps, followed by 1 ns NVE (300 K,
with harmonic constraints on the α-carbons) and 40 ns NPT (with the
harmonic constraints on the α-carbons) with a cutoﬀ of 9 Å,
constrained H-bonds, time step of 4 fs, Langevin damping at 0.1 ps−1,
and a PME frequency of 2 fs.47
Chemoinformatic Analyses. The chemical similarity of 30 N-
CBZ derivatives was characterized by calculating the algorithmic
distance using the R package ChemmineR (https://www.r-project.org,
https://www.bioconductor.org/packages/release/bioc/vignettes/
ChemmineR/inst/doc/ChemmineR.html, and ref 27). The com-
pounds were sorted by hierarchical clustering using the algorithmic
distance through the R package tool stats (https://www.r-project.org).
The heatmap of the thermophoresis shift data was generated by the R
package tool gplots.48
Compound Binding Sssays. Protein expression, microscale
thermophoresis assays, and Kd measurements were done as described
before.20 The raw data of the thermophoresis assays can be found in
Supporting Information, Table S4.
Pf Culture and L6 Toxicity Assays. Pf strain NF54 was cultured
in human erythrocytes according to Trager and Jensen49 and protocols
in www.mr4.org. The medium was RPMI 1640 supplemented with
0.5% ALBUMAX II, 25 mM Hepes, 25 mM NaHCO3 (pH 7.3), 0.36
mM hypoxanthine, and 100 μg/mL neomycin, and cultures were done
at 37 °C in a humidiﬁed atmosphere of 3% O2, 4% CO2, and 93% N2.
IC50 values were determined in vitro by measuring the incorporation
of the nucleic acid precursor [3H]hypoxanthine.50 Cytotoxicity was
assessed with L6 cells, a primary cell line derived from rat skeletal
myoblasts, as described elsewhere.51
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